uniQure N.V.
QURE
Market Cap$808.35M
Close$
$-2.53
120.6% downside
Current Fair Value
120.6% downsideOvervalued by 120.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $808.35 Million |
|---|---|
| Enterprise Value | $715.48 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-4.92 |
| Beta | 0.42 |
| Outstanding Shares | 48,840,666 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -3.01 |
|---|---|
| PEG | 5.97 |
| Price to Sales | - |
| Price to Book Ratio | -12.25 |
| Enterprise Value to Revenue | 25.03 |
| Enterprise Value to EBIT | -3.63 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.09 |
| Debt to Equity | -9.78 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About uniQure N.V.
uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to tr...